CINCINNATI / May 14, 2025 / Business Wire / Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the RBC Global Healthcare Conference on Wednesday, May 21, 2025, at approximately 9:30 a.m. (ET) at The InterContinental New York Barclay Hotel in New York City.
The audio webcast can be accessed by visiting the Chemed website at www.chemed.com (Investor Relations). The webcast replay will be available within 24 hours after the live presentation and will be accessible for 90 days.
Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation (www.chemed.com) operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care and Roto-Rooter is the nation’s leading provider of plumbing and drain cleaning services.
Statements in this press release or in other Chemed communications may relate to future events or Chemed's future performance. Such statements are forward-looking statements and are based on present information Chemed has related to its existing business circumstances. Investors are cautioned that such forward-looking statements are subject to inherent risk and that actual results may differ materially from such forward-looking statements. Further, investors are cautioned that Chemed does not assume any obligation to update forward-looking statements based on unanticipated events or changed expectations.
| Last Trade: | US$429.80 |
| Daily Change: | -5.53 -1.27 |
| Daily Volume: | 122,050 |
| Market Cap: | US$6.060B |
October 28, 2025 September 23, 2025 July 30, 2025 July 29, 2025 April 23, 2025 | |

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load